Charles Murdock, MD
Nephrology · Spartanburg, SCNPI 1679533640
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.2% of the total across 312 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations.
Across 312 payments — averaging $21.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Akebia Therapeutics Inc$1K
- AstraZeneca$566
- Vifor Pharma, Inc.$559
- Novartis$500
- Bayer$469
- Travere Therapeutics, Inc.$408
- plus $3K from 25 others
What the payments were for
- Food & beverage$6,39495%
- Education$3205%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Akebia Therapeutics Inc | 56 | $1,303 |
| AstraZeneca(2 entities) | 33 | $566 |
| Vifor Pharma, Inc. | 28 | $559 |
| Novartis | 20 | $500 |
| Bayer | 23 | $469 |
| Travere Therapeutics, Inc. | 19 | $408 |
| Mallinckrodt Hospital Products Inc. | 14 | $393 |
| GSK | 20 | $385 |
| Amgen(2 entities) | 16 | $334 |
| Calliditas Therapeutics US Inc. | 12 | $301 |
| ANI Pharmaceuticals, Inc. | 9 | $194 |
| Otsuka America Pharmaceutical, Inc. | 7 | $193 |
| Ardelyx, Inc. | 7 | $172 |
| Fresenius USA Marketing, Inc. | 8 | $134 |
| Novo Nordisk | 5 | $126 |
| Aurinia Pharma U.S., Inc. | 6 | $118 |
| Mallinckrodt Enterprises LLC | 6 | $113 |
| Boehringer Ingelheim | 4 | $90 |
| Daiichi Sankyo Inc. | 3 | $60 |
| Lilly USA, LLC | 3 | $56 |
| Ultragenyx Pharmaceutical Inc. | 2 | $33 |
| Apellis Pharmaceuticals, Inc. | 1 | $28 |
| Scpharmaceuticals Inc. | 1 | $28 |
| Arbor Pharmaceuticals, Inc. | 2 | $25 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Rockwell Medical, Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $21 |
| Seqirus USA Inc | 1 | $18 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| AbbVie | 1 | $11 |
How this compares
$6,715 in reported general payments places this provider in the 80th percentile of 180 nephrology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AuryxiaFerric Citrate | 113 | $155,105 |
| FarxigaDapagliflozin Propanediol | 112 | $94,123 |
| VelphoroSucroferric Oxyhydroxide | 31 | $70,848 |
| KerendiaFinerenone | 38 | $36,110 |
| JardianceEmpagliflozin | 32 | $36,093 |
| LokelmaSodium Zirconium Cyclosilicate | 18 | $15,123 |
| VeltassaPatiromer Calcium Sorbitex | 15 | $11,653 |
| XanaxAlprazolam | 12 | $10,799 |
| Calcium Acetate | 187 | $10,774 |
| EdarbiAzilsartan Medoxomil | 14 | $6,188 |
| Sevelamer Carbonate | 38 | $3,422 |
| Irbesartan | 59 | $2,607 |
| Nebivolol Hcl | 29 | $2,018 |
| Nifedipine ErNifedipine | 29 | $1,682 |
| Labetalol Hcl | 55 | $1,583 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Akebia Therapeutics IncAuryxia | $1,303 | $155,105113 claims |
| AstraZenecaFarxiga, Lokelma | $566 | $109,246130 claims |
| Fresenius USA Marketing, Inc.Velphoro | $134 | $70,84831 claims |
| BayerKerendia | $469 | $36,11038 claims |
| Boehringer IngelheimJardiance | $90 | $36,09332 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $25 | $6,18814 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $194 | $1,27521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 180 nephrology providers in South Carolina.
Other nephrology in Spartanburg
- Subhashini SubramaniamSpartanburg$13K
- Muhammad EbrahimSpartanburg$13K
- Tanya TangSpartanburg$11K
- Lawrence McGeeSpartanburg$11K
- Matthew LambertSpartanburg$9K
- Kofi AppiahSpartanburg$7K
- Jessica ColemanBeaufort$930K
- Moustafa MoustafaOrangeburg$616K
- Harold SzerlipCharleston$229K
- Barry GorlitskyGreenville$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.